Delivra Health Brands Inc

As of March 31, 2026, Delivra Health Brands Inc carries a market capitalization of 5.00M, placing it among publicly traded companies globally. Its enterprise value stands at 4.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Delivra Health Brands Inc's next confirmed earnings release is scheduled for October 23, 2026.

As of March 31, 2026, Delivra Health Brands Inc has 31.26M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 0.50, and the price-to-book ratio stands at 1.70.

These figures are as of March 31, 2026. The EV/Sales ratio of 0.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.70M versus a market cap of 5.00M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Delivra Health Brands Inc maintains a current ratio of 3.29, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 79.33, indicating elevated leverage, while an interest coverage ratio of -4.96 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Delivra Health Brands Inc posted a negative return on equity (ROE) of -53.83, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.05, reflecting losses generated across the asset base. Inventory turnover of 3.11 indicates how many times Delivra Health Brands Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on September 25, 2026, Delivra Health Brands Inc's stock has declined approximately 55.00% over the past 52 weeks. The 50-day moving average sits at 0.22, while the 200-day moving average is 0.26.

Over the twelve months ended March 31, 2026, Delivra Health Brands Inc generated 9.98M in revenue and converted that into -1.95M in net income, yielding earnings per share of -0.06. EBITDA reached -1.38M, while operating income came in at -1.73M.

As of March 31, 2026, Delivra Health Brands Inc holds 2.64M in cash and equivalents against 2.33M in total debt, resulting in a net debt position of -305,000.00. Total book value stands at 2.94M, with working capital of 4.96M providing operational flexibility.

Delivra Health Brands Inc produced -1.52M in operating cash flow over the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Delivra Health Brands Inc posted a gross margin of 43.44, reflecting its pricing power and cost economics. The operating margin of -17.35 and net profit margin of -19.56 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -30.35: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.38, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Delivra Health Brands Inc shareholders.

Delivra Health Brands Inc's most recent stock split took place on February 27, 2025 with a 10:1 split ratio.

As of March 31, 2026, Delivra Health Brands Inc has an Altman Z-Score of -31.62, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.